Back to News
Market Impact: 0.1
Beam Therapeutics Plans BEAM-304 Phase 1/2 Trial In PKU For Early 2027; Stock Up
Source: Nasdaq
Healthcare & BiotechCorporate Earnings
Beam Therapeutics reported third-quarter 2026 financial results and provided updates on clinical development programs targeting genetic diseases. The article excerpt gives no financial figures or specific program milestones.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
BEAM0.00
More News
- Beam earnings missed by $0.13, revenue fell short of estimates
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge
- AMD forecasts quarterly revenue above estimates as data-center revenue hits record
- UOB shares hit four-month low as Q3 profit misses analyst estimates
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace